The intestinal mucosal barrier plays an important role in the body’s protection against luminal pathogens and antigenic molecules; intercellular tight junctions (TJs), mainly composed of cytoplasmic proteins, including zona occludens (ZO) proteins, and two distinct transmembrane proteins, occludin and claudin, are the key structures responsible for intestinal epithelial barrier integrity (Turner, 2009). A dysregulation of one of this components, resulting in a paracellular permeability alteration, can lead to severe intestinal disorders, including inflammatory bowel disease (IBDs), the collective name for Crohn’s disease and ulcerative colitis, characterized by symptoms such as weight loss, diarrhoea, rectal bleeding, abdominal pain, fever and anemia (Cao et al, 2013). TNF-α-induced increase in intestinal epithelial tight junction permeability has been proposed to be an important proinflammatory mechanism contributing to intestinal inflammation in IBD, as demonstrated by the presence of markedly elevated levels of this cytokine in the intestinal tissue and serum of patients suffering from Crohn's disease (Ye et al, 2006). Although the molecular mechanism involved in intestinal barrier dysfunction caused by proinflammatory cytokines is still unclear and it represents a research focus in pathogenesis of IBD, it has been believed that NF-kB plays a very important role in the proinflammatory cytokines induced intestinal barrier disruption and in a downregulation of tight junction proteins expression. Recent studies support beneficial effects of anthocyanins, a class of flavonoid compounds that are widely distributed in mediterranean diet, in various chronic inflammatory diseases, such as IBDs. The aim of this work was to determine some of the intracellular mechanisms involved in TNF-α modulation of intestinal epithelial permeability by using an in vitro intestinal epithelial system consisting of filter grown Caco-2 monolayers and the effects exerted by Cyanidin-3-O-glucoside (C3G) pretreatment. Caco-2 cells exposure to TNF-α for 6 h activated IKK/NF-kB proinflammatory pathway, and induced COX-2 and IL6 expression. Interestingly, cells pretreatment for 24h with C3G (20 and 40 μM) was effective in preventing TNF-α-induced changes. Furthermore, C3G was able to improve intracellular redox status altered by TNF-α by increasing GSH levels and cellular antioxidant power. Furthermore, TNF-α exposure for 6h altered Caco-2 cells barrier permeability and integrity. C3G pretreatment prevented the increase in Caco-2 TJ permeability and epithelial barrier integrity. In conclusion, C3G showed anti-inflammatory properties through the modulation of NF-kB pathway and improved intestinal epithelial barrier integrity altered by TNF-α in Caco-2 cells. These data suggest that anthocyanins could contribute, as complementary approaches to the conventional already existing therapeutic approaches (i.e. non-steroidal anti-inflammatory drugs), to the management of IBDs (Romier et al, 2008).
Cyanidin-3-O-glucoside exhibits anti-inflammatory properties and improves intestinal epithelial barrier integrity in Caco-2 cells exposed to TNF-alpha
FERRARI, DANIELA;FRATANTONIO, DEBORAH;BASHLLARI, ROMINA;RANALDI, GIULIA;SAIJA, Antonina;CIMINO, Francesco;SPECIALE, ANTONIO
2015-01-01
Abstract
The intestinal mucosal barrier plays an important role in the body’s protection against luminal pathogens and antigenic molecules; intercellular tight junctions (TJs), mainly composed of cytoplasmic proteins, including zona occludens (ZO) proteins, and two distinct transmembrane proteins, occludin and claudin, are the key structures responsible for intestinal epithelial barrier integrity (Turner, 2009). A dysregulation of one of this components, resulting in a paracellular permeability alteration, can lead to severe intestinal disorders, including inflammatory bowel disease (IBDs), the collective name for Crohn’s disease and ulcerative colitis, characterized by symptoms such as weight loss, diarrhoea, rectal bleeding, abdominal pain, fever and anemia (Cao et al, 2013). TNF-α-induced increase in intestinal epithelial tight junction permeability has been proposed to be an important proinflammatory mechanism contributing to intestinal inflammation in IBD, as demonstrated by the presence of markedly elevated levels of this cytokine in the intestinal tissue and serum of patients suffering from Crohn's disease (Ye et al, 2006). Although the molecular mechanism involved in intestinal barrier dysfunction caused by proinflammatory cytokines is still unclear and it represents a research focus in pathogenesis of IBD, it has been believed that NF-kB plays a very important role in the proinflammatory cytokines induced intestinal barrier disruption and in a downregulation of tight junction proteins expression. Recent studies support beneficial effects of anthocyanins, a class of flavonoid compounds that are widely distributed in mediterranean diet, in various chronic inflammatory diseases, such as IBDs. The aim of this work was to determine some of the intracellular mechanisms involved in TNF-α modulation of intestinal epithelial permeability by using an in vitro intestinal epithelial system consisting of filter grown Caco-2 monolayers and the effects exerted by Cyanidin-3-O-glucoside (C3G) pretreatment. Caco-2 cells exposure to TNF-α for 6 h activated IKK/NF-kB proinflammatory pathway, and induced COX-2 and IL6 expression. Interestingly, cells pretreatment for 24h with C3G (20 and 40 μM) was effective in preventing TNF-α-induced changes. Furthermore, C3G was able to improve intracellular redox status altered by TNF-α by increasing GSH levels and cellular antioxidant power. Furthermore, TNF-α exposure for 6h altered Caco-2 cells barrier permeability and integrity. C3G pretreatment prevented the increase in Caco-2 TJ permeability and epithelial barrier integrity. In conclusion, C3G showed anti-inflammatory properties through the modulation of NF-kB pathway and improved intestinal epithelial barrier integrity altered by TNF-α in Caco-2 cells. These data suggest that anthocyanins could contribute, as complementary approaches to the conventional already existing therapeutic approaches (i.e. non-steroidal anti-inflammatory drugs), to the management of IBDs (Romier et al, 2008).Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.